GSKStock
Verdicts genuinely change. Free email alert the moment GSK's does — no target price to set, unlike a price alert.
Stable Ratio screen, 7 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
GSK is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
How the status reached this point
Non-compliant · status tracked since Nov 17, 2026
No change to GSK’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $101.2B as of 2026-09-07. At the 2026-11-18 close it is about $99.7B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 19.5% (19.2% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 4.6% (4.5% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 19.23% | 30.00% | Pass(10.8pp buffer) |
| Interest-bearing investments | 4.52% | 30.00% | Pass(25.5pp buffer) |
| Non-permissible income | 0.17% | 5.00% | Pass(4.8pp buffer) |
Usmani Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.65% | 33.00% | Pass(9.4pp buffer) |
| Interest-bearing investments | 5.56% | 33.00% | Pass(27.4pp buffer) |
| Non-liquid assets | 82.22% | at least 20.00% | Pass(62.2pp above the floor) |
| Non-permissible income | 0.17% | 5.00% | Pass(4.8pp buffer) |
MSCI Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.65% | 33.33% | Pass(9.7pp buffer) |
| Cash + interest-bearing securities | 5.56% | 33.33% | Pass(27.8pp buffer) |
| Accounts receivable | 17.78% | 33.33% | Pass(15.5pp buffer) |
| Non-permissible income | 0.17% | 5.00% | Pass(4.8pp buffer) |
FTSE Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.65% | 33.33% | Pass(9.7pp buffer) |
| Cash + interest-bearing securities | 5.56% | 33.33% | Pass(27.8pp buffer) |
| Accounts receivable | 17.78% | 50.00% | Pass(32.2pp buffer) |
| Non-permissible income | 0.17% | 5.00% | Pass(4.8pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.53% | 33.00% | Pass(11.5pp buffer) |
| Cash + interest-bearing securities | 5.06% | 33.00% | Pass(27.9pp buffer) |
| Accounts receivable | 11.13% | 33.00% | Pass(21.9pp buffer) |
| Non-permissible income | 0.17% | 5.00% | Pass(4.8pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.76% | 33.00% | Pass(10.2pp buffer) |
| Cash + interest-bearing securities | 5.35% | 49.00% | Pass(43.6pp buffer) |
| Accounts receivable | 11.77% | 49.00% | Pass(37.2pp buffer) |
| Non-permissible income | 0.17% | 5.00% | Pass(4.8pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.76% | 33.33% | Pass(10.6pp buffer) |
| Cash + interest-bearing securities | 5.35% | 33.33% | Pass(28.0pp buffer) |
| Accounts receivable | 17.12% | 49.00% | Pass(31.9pp buffer) |
| Non-permissible income | 0.17% | 5.00% | Pass(4.8pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from GSK's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $43.1B | 2025-12-31 | Revenue |
| Interest-bearing debtShort and long-term borrowings | $19.5B | 2025-12-31 | Borrowings |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $4.6B | 2025-12-31 | CashAndCashEquivalents |
| Total assetsBalance sheet total | $82.3B | 2025-12-31 | Assets |
| Market capDenominator for AAOIFI | $101.2B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $173.6B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $183.3B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $73.8M | 2025-12-31 | InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2025-12-31. Income statement as of 2025-12-31. Screened 2026-09-07.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$82.3B
Assets· balance sheet as of 2025-12-31 -
Interest-bearing debt$19.5B
Borrowings· balance sheet as of 2025-12-31 -
Cash and interest-bearing securities$4.6B
CashAndCashEquivalents· balance sheet as of 2025-12-31 -
Receivables$10.1B
TradeAndOtherCurrentReceivables· balance sheet as of 2025-12-31 -
Revenue$43.1B
Revenue· income statement as of 2025-12-31 -
Interest income (non-permissible)$73.8M
InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost· income statement as of 2025-12-31 -
Market cap$101.2BMarket-data quote at screen time, 2026-09-07 · not a filing figure, so no link
What changed, and when
Verdict history for GSK. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-09 Compliant → Non Compliant watchlist re-scan
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 7 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2025-12-31; market cap as stored on 2026-09-07.
No standard's deciding ratio sits within 3 points of its line.
The ratios that move with the share price
AAOIFI's debt ratio is $19.5B debt over a market cap of $101.2B (as of 2026-09-07), 19.2% against a 30% line.
At the 2026-11-18 close the market cap is about $99.7B (the stored cap moved by the share price since), so this ratio would read 19.5%; the line is -35% from there. The published status changes only when the company is re-screened.
It would fail if the market cap fell to $64.9B (-36%).
AAOIFI would then fail; the majority verdict would stay Not compliant (6 of 7 decided standards passing), because it is held (Zoya rates it not compliant, and our screen does not overrule another screener's doubt).
At the screen's market cap, debt would have to rise by $10.9B to reach the line.
AAOIFI would then fail; the majority verdict would stay Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).
AAOIFI's investments ratio (4.5% against a 30% line) would only fail if the market cap fell by 85%, to $15.2B. At the 2026-11-18 close it would read 4.6%.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| LLYLilly(Eli) & Co | $1.2T | — |
| JNJJohnson & Johnson | $658.0B | — |
| ABBVAbbvie Inc | $467.4B | — |
| MRKMerck & Co Inc | $371.7B | — |
| NVSNovartis AG - ADR | $306.5B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold GSK
5 of the 182 funds whose filed holdings we currently hold own GSK shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns GSK.
Shariah fundsGSK fails our screen. These funds follow their own Shariah screens, which can reach a different answer from ours on the same company.
| Fund | GSK in fund | Fund compliant by weight |
|---|---|---|
| UMMA Wahed Dow Jones Islamic World ETF | 1.01% | 89% |
| SPWO SP Funds S&P World (ex-US) ETF | 0.53% | 87% |
| Fund | GSK in fund | Fund compliant by weight |
|---|---|---|
| SUIAX DWS CROCI (R) International Fund Also SUIIX | 1.01% | 35% |
| IFTAX Voya International High Dividend Low Volatility Portfolio | 0.50% | 23% |
| AAAIX Strategic Allocation: Aggressive Fund | 0.02% | not computed |
Sorted by GSK’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names GSK once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Dodge & Cox | Dodge & Cox | $2,080M | 1.1% | 2026-09-30 |
| Ken Fisher | Fisher Asset Management | $1,703M | 0.5% | 2026-09-30 |
| Hotchkis & Wiley | Hotchkis & Wiley Capital Management | $189M | 0.5% | 2026-09-30 |
| Jeremy Grantham | GMO | $189M | 0.4% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $97M | 0.0% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $89M | 0.0% | 2026-09-30 |
| Charles Brandes | Brandes Investment Partners | $72M | 0.5% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $26M | 0.1% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $22M | 0.0% | 2026-09-30 |
| Peter Schiff | Euro Pacific Asset Management | $10M | 0.8% | 2026-09-30 |
| Kahn Brothers | Kahn Brothers Group | $5M | 0.9% | 2026-09-30 |
| Mark Hillman | Hillman Capital Management | $4M | 3.3% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $4M | 0.0% | 2026-09-30 |
| Tweedy, Browne | Tweedy, Browne Company | $4M | 0.3% | 2026-09-30 |
| Saturna Capital | Amana Mutual Funds Trust | $2M | 0.0% | 2026-09-30 |
| Richard Pzena | Pzena Investment Management | $1M | 0.0% | 2026-09-30 |
| Jeff Auxier | Auxier Asset Management | $1M | 0.2% | 2026-09-30 |
| Sallie Krawcheck | Ellevest | $1M | 0.1% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 44.50 | NEUTRAL |
| Stochastic %K (14) | 12.14 | BUY |
| CCI (20) | -78.53 | NEUTRAL |
| Williams %R (14) | -87.86 | BUY |
| MACD (12,26,9) | -0.13 | SELL |
| ROC (10) | -4.17 | SELL |
| Momentum (10) | -2.11 | SELL |
| EMA (10) | 49.73 | SELL |
| SMA (10) | 50.07 | SELL |
| EMA (20) | 49.60 | SELL |
| SMA (20) | 49.81 | SELL |
| EMA (30) | 49.45 | SELL |
| SMA (30) | 49.15 | SELL |
| EMA (50) | 49.39 | SELL |
| SMA (50) | 48.91 | SELL |
| EMA (100) | 49.66 | SELL |
| SMA (100) | 49.83 | SELL |
| EMA (200) | 50.18 | SELL |
| SMA (200) | 51.38 | SELL |
About GSK
Healthcare · Drug Manufacturers - General
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-10-29
Stop 48.32 Now 48.58 Target 50.80
Average — needs more confirmation before sizing up
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 54 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.